08:39 AM EDT, 08/15/2024 (MT Newswires) -- Silence Therapeutics ( SLN ) reported a Q2 loss of 11.1 British pence ($0.14) per diluted share, wider than its loss of 9.6 pence a year earlier.

One analyst polled by Capital IQ expected a loss of 0.06 pence per share.

Revenue for the quarter ended June 30 was 598,000 pounds, down from 9.1 million pounds a year earlier.

Two analysts polled by Capital IQ expected 9.9 million pounds.

As of June 30, Silence had 149.6 million pounds in cash, cash equivalents and US Treasury Bills.

Shares of the company were down 2.1% in recent Thursday premarket activity.